SCHEMBL5834744

SCHEMBL5834744

NCc1cccc(CNC(=O)C(F)(F)F)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.51
CYP2D6 P10635 2/20 0.51
CYP2C19 P33261 2/20 0.51
CYP2C9 P11712 1/20 0.51
TSHR P16473 1/20 0.51
HTR2C P28335 1/20 0.50
CFD P00746 1/20 0.47
TPSAB1 Q15661 3/20 0.46
MLYCD O95822 1/20 0.46
AOC3 Q16853 2/20 0.44
BACE1 P56817 2/20 0.44
LOXL2 Q9Y4K0 1/20 0.44
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44
HRH3 Q9Y5N1 1/20 0.43
KLKB1 P03952 1/20 0.43
KLK1 P06870 1/20 0.43
BACE2 Q9Y5Z0 1/20 0.43
FPR3 P25089 1/20 0.43
FPR2 P25090 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23254961 0.86 TPSAB1 (0.61) CYP1A2CYP2D6CYP2C19CYP2C9TSHR
SCHEMBL2777304 0.85 PDK1 (0.48) CYP1A2CYP2D6CYP2C19MLYCDALDH1A1
Hydrochloric Acid SCHEMBL23148228 0.85 TPSAB1 (0.59) CYP1A2CYP2D6CYP2C19CYP2C9TSHR
SCHEMBL624565 0.84 CYP1A2 (0.51) CYP1A2CYP2D6CYP2C19CYP2C9TSHR
SCHEMBL13501586 0.84 HDAC3 (0.50) CYP1A2CYP2D6CYP2C19MLYCDALDH1A1
SCHEMBL2252763 0.84 NAMPT (0.47) CYP1A2CYP2D6CYP2C19CYP2C9TSHR
SCHEMBL15680103 0.83 CYP1A2 (0.50) CYP1A2CYP2D6CYP2C19CYP2C9TSHR
SCHEMBL7663169 0.82 CYP1A2 (0.51) CYP1A2CYP2D6CYP2C19MLYCDENPP2
SCHEMBL13738172 0.82 SRC (0.54) MLYCDALDH1A1HPGD
SCHEMBL30491754 0.81 F10 (0.56) HTR2CMLYCDENPP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7101878-B1 Non-peptide GNRH agents, methods and intermediates for their preparation AGOURON PHARMACEUTICALS, INC. (US) 2006-09-05 US disclosed
EP-1105120-B1 NON-PEPTIDE GnRH AGENTS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION AGOURON PHARMA (US) 2005-03-23 EP disclosed
EP-1401427-A4 NON-PEPTIDE GNRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USES, AND PROCESSES FOR PREPARING THEM AGOURON PHARMA (US) 2004-12-01 EP disclosed
EP-1401427-A2 NON-PEPTIDE GNRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USES, AND PROCESSES FOR PREPARING THEM Agouron Pharmaceuticals, Inc. (US) 2004-03-31 EP disclosed
WO-2002098363-A2 NON-PEPTIDE GnRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USES, AND PROCESSES FOR PREPARING THEM AGOURON PHARMACEUTICALS, INC. (US) 2002-12-12 WO disclosed
EP-1105120-A4 NON-PEPTIDE GnRH AGENTS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION AGOURON PHARMA (US) 2001-12-19 EP disclosed
EP-1105120-A2 NON-PEPTIDE GnRH AGENTS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION AGOURON PHARMACEUTICALS, INC. (US) 2001-06-13 EP disclosed
WO-2000020358-A2 NON-PEPTIDE GnRH AGENTS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION AGOURON PHARMACEUTICALS, INC. (US) 2000-04-13 WO disclosed